WA-CYEMPTIVE
Cyemptive Technologies, an award-winning provider of pre-emptive cybersecurity solutions for business and government, today announced that it has entered into a liaison partnership with Partnership for Cyber Security Innovation (PCSI) in the Netherlands.
PCSI is a public/private sector network of government bodies, research institutes, corporations and startups/scaleups and designed to make Dutch society more secure and resilient against future cyber-attacks. Its major partners include leading public and private sector organizations such as ABN Amro, Achmea, ASML, ING, Dutch Tax & Customs Administration and TNO.
“I am excited that Cyemptive joins the PCSI ecosystem as a Liaison Partner,” said Reinder Wolthuis, Program Manager PCSI. “PCSI is about innovation and collaboration. As a relatively young and innovative cybersecurity company and Cyemptive’s mission to transform the cybersecurity industry to a fully proactive approach, Cyemptive is a natural fit for PCSI.”
PCSI is an open innovation platform that aims to make Dutch society more secure and resilient against future cyber-attacks. By giving them a platform for sharing knowledge and expertise, PCSI offers its core partners a unique opportunity to develop innovative cybersecurity solutions that boost the cyber resilience of both individual companies and Dutch society in general. The innovation projects include a variety of cybersecurity challenges, from advanced detection systems to software for structuring data automatically and human-factor solutions.
“Being part of PCSI provides organizations with a platform to influence cybersecurity policies and standards,” said Rob Pike, founder and CEO of Cyemptive. “This ensures that their specific needs and concerns are considered in the development of industry regulations and guidelines.”
Cyemptive offers military-grade layers of pre-emptive cybersecurity protection that are essential add-ons for businesses to achieve cyber safety. Cyemptive’s ZeroStrike allows customers to be in command of their security by eliminating damage even from unknown attack vectors pre-zero day discovery. With Cyemptive ZeroStrike there is no need for recovery and remediation, an industry first capability.
About PCSI
Partnership for Cyber Security Innovation makes a vital contribution to a secure and resilient digital society through innovation in cybersecurity. Within PCSI, applicable, innovative cybersecurity solutions are developed that allow stakeholders in Dutch society to protect themselves against the cyber-attacks of tomorrow. By working together closely via an innovative ecosystem, PCSI partners connect applied research, current data and issues from society in the field of cybersecurity in a unique way.
About Cyemptive Technologies
Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 11 ‘ASTORS’ Homeland Security Awards from American Security Today in 2023 and received 10 awards in 2022 – more than any other company. Cyemptive’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707748050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom